News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
長風藥業(02652.HK)ICF004 I類新藥臨床試驗申請獲內地批准
長風藥業(02652.HK)公布，ICF004吸入粉霧劑之I類新藥臨床試驗(IND)申請近期已獲得中國國家藥品監督管理局(NMPA)批准。該產品擬用於治療間質性肺病(ILD)，包括但不限於特發性肺纖維化(IPF)及進行性肺纖維化(PPF)。(jl/da)~阿思達克財經新聞網址: www.aastocks.com
Reset
Send
The window will close in 5 seconds
長風藥業(02652.HK)ICF004 I類新藥臨床試驗申請獲內地批准
Close
Recommend
2
Positive
1
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

長風藥業(02652.HK)  +0.170 (+0.938%)    Short selling $27.26K; Ratio 0.315%   公布，ICF004吸入粉霧劑之I類新藥臨床試驗(IND)申請近期已獲得中國國家藥品監督管理局(NMPA)批准。

該產品擬用於治療間質性肺病(ILD)，包括但不限於特發性肺纖維化(IPF)及進行性肺纖維化(PPF)。(jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-15 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.